This product is a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human DIXDC1 gene in HAP1 cells. The polyclonal format provides a heterogeneous pool of cells with diverse gene disruption events, enabling robust loss-of-function studies without the need for single-cell cloning. This model allows researchers to interrogate DIXDC1-dependent signaling in a near-haploid background, facilitating functional genomics experiments and drug discovery applications within the Wnt pathway.
HAP1 is a human near-haploid fibroblast-like cell line derived from the male chronic myeloid leukemia cell line KBM-7. Its haploid genome simplifies knockout generation, as disruption of a single allele yields complete gene inactivation, thereby minimizing off-target concerns and enhancing phenotypic penetrance. The adherent, fibroblast-like morphology is compatible with standard cell culture techniques and supports automated high-throughput screening platforms and detailed imaging-based assays.
DIXDC1 encodes a DIX domain-containing scaffold protein that functions as a positive regulator of canonical Wnt/??-catenin signaling. Mechanistically, DIXDC1 interacts with Dishevelled-2 (Dvl2) and Axin, facilitating disassembly of the ??-catenin destruction complex and leading to ??-catenin stabilization and nuclear translocation. Nuclear ??-catenin partners with TCF/LEF transcription factors to drive expression of target genes such as MYC, CCND1, and AXIN2. Upstream activation is triggered by Wnt ligands like Wnt3a through Frizzled receptors and LRP5/6 co-receptors, positioning DIXDC1 downstream of receptor activation. Additionally, DIXDC1 associates with DISC1, linking Wnt signaling to neurodevelopmental processes.
The near-haploid nature of HAP1 cells enhances the utility of DIXDC1 knockout for dissecting Wnt pathway dynamics. Because genetic redundancy is reduced, loss of DIXDC1 directly impacts ??-catenin-dependent transcription, cell proliferation, and differentiation. This model is particularly valuable for drug target validation in Wnt-driven cancers such as colorectal and hepatocellular carcinomas, where DIXDC1 is frequently dysregulated. The polyclonal population also allows evaluation of heterogeneous knockout effects on pathway output, mimicking complex in vivo conditions.
Researchers can employ this knockout model in diverse experimental paradigms. Western blotting and RT-qPCR confirm DIXDC1 loss and quantify changes in ??-catenin protein levels and TCF/LEF target gene expression. Functional assays like TOPFlash/FOPFlash luciferase reporters provide quantitative readouts of Wnt transcriptional activity. Co-immunoprecipitation studies assess DIXDC1 interactions with Dvl2 and Axin. Cell proliferation, migration, and invasion assays probe tumorigenic phenotypes, while drug sensitivity screening with Wnt inhibitors such as ICG-001 or XAV939 can identify therapeutic vulnerabilities. For further details or to discuss application-specific validation, please contact Ascent Research.
